Platelet Mitochondrial Respiration, Endogenous Coenzyme Q10 and Oxidative Stress in Patients with Chronic Kidney Disease

Abstract

Chronic kidney disease (CKD) is characterized by a progressive loss of renal function and a decrease of glomerular filtration rate. Reduced mitochondrial function, coenzyme Q10 (CoQ10), and increased oxidative stress in patients with CKD contribute to the disease progression. We tested whether CoQ10 levels, oxidative stress and platelet mitochondrial bioenergetic function differ between groups of CKD patients. Methods: Twenty-seven CKD patients were enrolled in this trial, 17 patients had arterial hypertension (AH) and 10 patients had arterial hypertension and diabetes mellitus (AH and DM). The control group consisted of 12 volunteers. A high-resolution respirometry (HRR) method was used for the analysis of mitochondrial bioenergetics in platelets, and an HPLC method with UV detection was used for CoQ10 determination in platelets, blood, and plasma. Oxidative stress was determined as thiobarbituric acid reactive substances (TBARS). Results: Platelets mitochondrial respiration showed slight, not significant differences between the groups of CKD patients and control subjects. The oxygen consumption by intact platelets positively correlated with the concentration of CoQ10 in the platelets of CKD patients. Conclusion: A decreased concentration of CoQ10 and oxidative stress could contribute to the progression of renal dysfunction in CKD patients. The parameters of platelet respiration assessed by high-resolution respirometry can be used only as a weak biological marker for mitochondrial diagnosis and therapy monitoring in CKD patients.

Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19?

“…Low levels of CoQ 10 may be caused by a damage to endogenous CoQ 10 synthesis, or by mutation of one or more of the COQ genes, or by its increased utilization. Signifi cantly lower serum level of CoQ 10 were found in patients with an acute infl uenza infection (15), in patients with chronic kidney disease (38,39), in endomyocardial biopsies of patients after heart transplantation (40) in patients with cardiomyopathy (41), in infertile men (42,43). CoQ 10 has shown the potential to decrease pain and fatigue in patients with fi bromyalgia (44).…”

Human Platelet Mitochondrial Function Reflects Systemic Mitochondrial Alterations: A Protocol for Application in Field Studies

“…Hence, metabolically highly active but homogenous PLTs might be a valuable surrogate to investigate systemic changes of mitochondrial function, since they are involved in a variety of systemic reactions (e.g., hemostasis, immunoregulation, inflammation or oxidative stress) [18][19][20]. Assessing PLT bioenergetics as a systemic marker has been performed in the context of various diseases [15,19,[21][22][23][24][25][26][27][28] as well as training studies [29][30][31][32][33]. However, changes in PLT bioenergetics after an ultramarathon competition in the context of a field study has not been assessed so far.…”

Platelet Mitochondrial Bioenergetics Reprogramming in Patients with Urothelial Carcinoma

“…Platelets isolated from peripheral blood are an accessible source of mitochondria studied in various diseases, such as lateral amyloid sclerosis [ 10 ], in patients with chronic kidney disease [ 11 , 12 ], in a patient after kidney transplantation [ 13 ], in patients with rheumatoid arthritis [ 14 ], and in aging [ 15 ]. Our previous study showed a reduced platelet mitochondrial metabolism and endogenous CoQ 10 concentration in non-hospitalized patients after 3–6 weeks of acute COVID-19 disease (in platelets, CoQ 10 was reduced vs. control to 70%, p = 0.002) [ 16 ].…”